Ernexa Therapeutics Inc (ERNA) FinancialsERNAErnexa Therapeutics Inc

Ernexa Therapeutics Inc (ERNA) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Subscription revenue, accounting for 93.9% of total sales, equivalent to $1.10M. Other significant revenue streams include Other revenue and Hardware revenue. Understanding this composition is critical for investors evaluating how ERNA navigates market cycles within the Biotechnology & Medical Research industry.

Evaluating the bottom line, Ernexa Therapeutics Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -321.22%, provide a clear picture of how effectively ERNA converts its operational activities into shareholder value.

In the context of the broader market, ERNA competes directly with industry leaders such as KALA and MBIO. With a market capitalization of $3.06M, it holds a leading position in the sector. When comparing efficiency, ERNA's gross margin of N/A stands against KALA's N/A and MBIO's N/A. Such benchmarking helps identify whether Ernexa Therapeutics Inc is trading at a premium or discount relative to its financial performance.

Eterna Therapeutics has reported no revenue for multiple quarters, with significant net losses, including -5.51 million in Q1 2026. The gross margin is projected to be 0% for the next several quarters, indicating no profitability.